Rheumatology

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment (unless specifically indicated) and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Antiphospholipid syndrome – catastrophic

Recommended Indications in which IG can be used

Order Number: R1-ASC

Antiphospholipid syndrome (other than catastrophic)

Do Not Use

Autoimmune retinopathy (AIR)

Recommended Indications in which IG can be used

Order Number: R1-AIR

Behçet disease

Do Not Use

Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss disease)

Recommended Indications in which IG can be used

Order Number: R3-EGPA

Idiopathic Inflammatory myopathy (IIM)

Recommended Indications in which IG can be used

Order Number: R4-IIM

Inclusion body myositis (IBM)

Do Not Use

Juvenile Idiopathic Inflammatory Myopathy (J-IIM)(Previously Juvenile Dermatomyositis)

Recommended Indications in which IG can be used

Order Number: R5-JIIM

Kawasaki Disease

Recommended Indications in which IG can be used

Order Number: R6-KD

Macrophage activation syndrome (MAS)

Recommended Indications in which IG can be used

Order Number: R7-MAS